ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 244,62
-0,41%
Dow Jones
42 840,26
1,18%
DAX
19 838,33
-0,39%
Brent Oil
72,79
0,10%
Bitcoin
95 221,61
0,12%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) Actualités

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ELTX
DateHeureSourceTitreSymboleSociété
18/12/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
12/12/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
12/12/202413h00GlobeNewswire Inc.Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024NASDAQ:ELTXElicio Therapeutics Inc
03/12/202413h00GlobeNewswire Inc.Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentNASDAQ:ELTXElicio Therapeutics Inc
22/11/202414h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELTXElicio Therapeutics Inc
21/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
13/11/202422h21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
13/11/202422h05GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
07/11/202422h05GlobeNewswire Inc.Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
31/10/202413h30GlobeNewswire Inc.Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation SummitNASDAQ:ELTXElicio Therapeutics Inc
16/10/202414h30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
27/09/202422h42Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELTXElicio Therapeutics Inc
27/09/202422h41Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
17/09/202422h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
13/09/202414h30GlobeNewswire Inc.Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile VaccinesNASDAQ:ELTXElicio Therapeutics Inc
28/08/202414h00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
13/08/202422h30GlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
12/08/202422h05GlobeNewswire Inc.Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible NoteNASDAQ:ELTXElicio Therapeutics Inc
28/06/202415h00GlobeNewswire Inc.Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202422h05GlobeNewswire Inc.Elicio Therapeutics Announces Proposed Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202422h01GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7PNASDAQ:ELTXElicio Therapeutics Inc
03/06/202422h41Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ELTXElicio Therapeutics Inc
23/05/202423h30GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
15/05/202422h30GlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
25/04/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
05/04/202422h30GlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
29/03/202413h30GlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
05/02/202414h30GlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
25/01/202415h00GlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX

Dernières Valeurs Consultées

TSXV
PRO
Pershimex Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés